Neurology · PANCE / PANRE

Restless Legs Syndrome (Willis-Ekbom Disease)

Sensorimotor disorder with an urge to move the legs at rest, relieved by movement, worse in the evening.

Also known as: RLS, Willis-Ekbom disease, restless leg syndrome

Overview

A sensorimotor disorder characterized by an irresistible urge to move the legs, usually accompanied by uncomfortable sensations, that begins or worsens at rest, is partially or fully relieved by movement, and is worse in the evening or at night (URGE mnemonic / IRLSSG essential criteria).

Epidemiology

Prevalence 5-10% in adults of European descent; lower in Asian populations. Female predominance ~2:1. Onset peaks before age 20 (primary, familial) and again in middle-late adulthood. ~40-60% report a positive family history.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Restless Legs Syndrome (Willis-Ekbom Disease) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Iron deficiency or low body iron stores (serum ferritin <75-100 ng/mL is a treatable contributor)
Chronic kidney disease, especially on hemodialysis
Pregnancy (especially third trimester)
Family history of RLS (autosomal dominant with variable penetrance; risk loci include MEIS1, BTBD9)
Medications: SSRIs/SNRIs, tricyclic antidepressants, mirtazapine, dopamine antagonists (antiemetics, antipsychotics), antihistamines (diphenhydramine)
Peripheral neuropathy
Multiple sclerosis, Parkinson disease
Caffeine, alcohol, nicotine

Pathophysiology

Best understood as a brain iron deficiency state with altered central dopaminergic, glutamatergic, and adenosine signaling. CSF ferritin is low even with normal serum ferritin in many patients. Genetic variants in MEIS1, BTBD9, and PTPRD confer risk. Periodic limb movements of sleep (PLMS) commonly coexist.

Clinical presentation

Symptoms

Uncomfortable, hard-to-describe sensations: crawling, tingling, itching, pulling, electric, 'creepy-crawly'
Urge to move legs, sometimes arms, especially when sitting still or trying to fall asleep
Relief with walking, stretching, or rubbing the legs
Worse in evening and at night — circadian pattern
Insomnia and daytime fatigue
Partner reports periodic kicking or jerking during sleep (PLMS)

Signs / physical exam

Neurologic exam typically normal in primary RLS
Look for signs of peripheral neuropathy (stocking sensory loss, absent ankle reflexes) that may indicate secondary RLS
Pallor or cheilosis suggesting iron deficiency anemia

Classic findings

Adult with bedtime urge to move legs that resolves with walking, partner-witnessed leg kicks during sleep, and low ferritin.

Differential diagnosis

Peripheral neuropathy — Constant paresthesias, sensory deficit, reduced reflexes; not worse at rest or relieved by movement
Akathisia (drug-induced) — Inner restlessness involving whole body, not relieved by movement; recent neuroleptic, antiemetic, or SSRI
Nocturnal leg cramps — Painful sudden cramps relieved by stretching; not associated with urge to move
Vascular claudication — Walking-induced calf pain relieved by rest — opposite pattern
Anxiety with motor restlessness — Generalized restlessness, no temporal pattern, no relief with movement
Periodic limb movement disorder (PLMD) — Stereotyped movements during sleep without subjective urge; often coexists with RLS

Diagnostic workup

Diagnostic criteria

IRLSSG essential criteria (all 5): (1) urge to move legs, usually with uncomfortable sensations; (2) begins or worsens during rest/inactivity; (3) partially or totally relieved by movement; (4) worse in the evening or night; (5) not solely accounted for by another condition (cramps, positional discomfort, neuropathy).

Labs

Ferritin and transferrin saturation — the most important laboratory test; treat to ferritin >75-100 ng/mL
CBC, BMP, BUN/Cr (CKD evaluation)
TSH, fasting glucose/A1c, B12 if neuropathy suspected
Medication and substance review (SSRIs, antihistamines, dopamine antagonists, caffeine, alcohol)

Imaging

Routine imaging not indicated
Polysomnography reserved for diagnostic uncertainty or to evaluate PLMS / coexisting sleep apnea

Diagnostic algorithm

flowchart TD
  A[Urge to move legs<br/>worse at rest/night,<br/>relieved by movement] --> B[Meet IRLSSG<br/>5 essential criteria]
  B --> C[Check ferritin,<br/>review medications,<br/>screen for CKD/<br/>pregnancy/neuropathy]
  C --> D{Ferritin<br/>&lt;75-100?}
  D -->|Yes| E[Oral or IV iron]
  D -->|No| F[Initial therapy:<br/>alpha-2-delta ligand<br/>(gabapentin enacarbil,<br/>pregabalin)]
  F --> G{Refractory or<br/>severe?}
  G -->|Yes| H[Dopamine agonist<br/>(low dose) OR<br/>low-dose opioid]
  H --> I{Augmentation<br/>on DA?}
  I -->|Yes| J[Reduce DA,<br/>switch to gabapentinoid<br/>or opioid]
  G -->|No| K[Continue,<br/>optimize sleep,<br/>recheck ferritin]

Stepwise management of restless legs syndrome with augmentation pathway.

Treatment

First-line

Iron repletion if ferritin <75-100 ng/mL: oral iron (ferrous sulfate 325 mg with vitamin C every other day) OR IV iron (ferric carboxymaltose, iron sucrose) for severe or oral-intolerant cases
Alpha-2-delta calcium channel ligands — gabapentin enacarbil 600-1200 mg, pregabalin 150-450 mg, or gabapentin 300-1200 mg at bedtime; preferred over dopamine agonists due to lower augmentation risk
Dopamine agonists — pramipexole 0.125-0.5 mg, ropinirole 0.25-4 mg, rotigotine patch 1-3 mg/24 h — NO LONGER recommended as standard/first-line therapy (AASM 2024 conditionally recommends against routine use) because of augmentation and impulse-control disorder risk; reserve for selected cases at lowest effective dose
Sleep hygiene; reduce caffeine, alcohol, nicotine; identify and stop aggravating medications when possible

Augmentation management

Augmentation = paradoxical worsening of symptoms with chronic dopamine agonist use (earlier onset, spread to arms, increased intensity)
Reduce/cross-taper dopamine agonist; optimize ferritin
Switch to alpha-2-delta ligand or low-dose opioid
Avoid escalating dopamine agonist dose, which worsens augmentation

Severe/refractory RLS

Low-dose long-acting opioids (oxycodone CR, methadone, buprenorphine) — reserved for refractory disease with shared decision-making about risks
Combination of alpha-2-delta ligand + dopamine agonist or opioid
Address coexisting OSA

Pregnancy

Optimize iron stores; oral iron preferred
Non-pharmacologic measures (stretching, leg massage, warm baths, pneumatic compression)
Avoid dopamine agonists and gabapentinoids in first trimester when possible; clonazepam or low-dose opioid only if severely impairing sleep

Second-line / adjunct

Pneumatic compression devices
Yoga, exercise, mindfulness
Treat coexisting OSA — CPAP can improve RLS symptoms

Complications

Chronic insomnia and daytime fatigue
Depression and anxiety
Augmentation with chronic dopamine agonist therapy
Impulse control disorders (pathologic gambling, hypersexuality, binge eating) with dopamine agonists
Opioid use disorder if opioids required long-term

PANCE pearls

Check ferritin in every patient with RLS — target >75-100 ng/mL even if hemoglobin is normal.
Gabapentinoids are increasingly favored over dopamine agonists as first-line pharmacotherapy due to augmentation risk.
Augmentation differs from tolerance: symptoms appear earlier in the day, are more intense, and spread to new body parts.
Diphenhydramine, metoclopramide, and SSRIs are common iatrogenic triggers — review medications carefully.
Severe iron-deficient RLS responds dramatically to IV iron — consider in patients with persistent symptoms despite oral therapy.

References

AASM 2024 — Winkelman JW et al. Treatment of restless legs syndrome and periodic limb movement disorder: An AASM clinical practice guideline. J Clin Sleep Med 2024 (latest version).
IRLSSG — Allen RP et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated IRLSSG consensus criteria. Sleep Med 2014;15:860-873.
IRLSSG Iron Consensus — Allen RP et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of RLS/WED. Sleep Med 2018;41:27-44.

Practice Neurology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.